作者
Adam K Wheatley, Phillip Pymm, Robyn Esterbauer, Melanie H Dietrich, Wen Shi Lee, Damien Drew, Hannah G Kelly, Li-Jin Chan, Francesca L Mordant, Katrina A Black, Amy Adair, Hyon-Xhi Tan, Jennifer A Juno, Kathleen M Wragg, Thakshila Amarasena, Ester Lopez, Kevin J Selva, Ebene R Haycroft, James P Cooney, Hariprasad Venugopal, Li Lynn Tan, Matthew TO Neill, Cody C Allison, Deborah Cromer, Miles P Davenport, Richard A Bowen, Amy W Chung, Marc Pellegrini, Mark T Liddament, Alisa Glukhova, Kanta Subbarao, Stephen J Kent, Wai-Hong Tham
发表日期
2021/10/12
期刊
Cell Reports
卷号
37
期号
2
出版商
Elsevier
简介
Potent neutralizing monoclonal antibodies are one of the few agents currently available to treat COVID-19. SARS-CoV-2 variants of concern (VOCs) that carry multiple mutations in the viral spike protein can exhibit neutralization resistance, potentially affecting the effectiveness of some antibody-based therapeutics. Here, the generation of a diverse panel of 91 human, neutralizing monoclonal antibodies provides an in-depth structural and phenotypic definition of receptor binding domain (RBD) antigenic sites on the viral spike. These RBD antibodies ameliorate SARS-CoV-2 infection in mice and hamster models in a dose-dependent manner and in proportion to in vitro, neutralizing potency. Assessing the effect of mutations in the spike protein on antibody recognition and neutralization highlights both potent single antibodies and stereotypic classes of antibodies that are unaffected by currently circulating VOCs, such …
学术搜索中的文章
AK Wheatley, P Pymm, R Esterbauer, MH Dietrich… - Cell Reports, 2021